Drugs / BFPET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02252783 | Oct 2018 → May 2019 | coronary artery disorder | Fluoropharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BFPET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02252783 ↗ |
| Modality | Diagnostic / imaging agent | “BFPET will be evaluated as a diagnostic PET agent” NCT02252783 ↗ |
| Route | Intravenous | “The drug will be administered intravenously by bolus injection” NCT02252783 ↗ |